Odense C

• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended recruitment
  2023-509662-38-00 4 2025-01-22 Type 2 diabetes and painful diabetic peripheral neuropathy
• A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended recruitment
  2024-514228-18-00 4 2025-01-16 Asthma in adults who remain uncontrolled despite medium to high dose I
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients. - The PIPAC-OPC3 CC trial Ended recruitment
  2024-519189-31-00 4 2024-12-04 Colon cancer
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• An exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026 to assess safety, tolerability, and efficacy in p … Ended recruitment
  2023-509182-21-00 4 2024-09-16 Patients with ST-Elevation Myocardial Infarction (STEMI)
• Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III tri … Ended recruitment
  2023-503644-13-00 5 2024-09-09 Breast cancer-related lymphedema
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended recruitment
  2023-505746-25-00 4 2024-07-16 Cold agglutinin disease
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot … Ended recruitment
  2023-506668-15-00 5 2024-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f … Ended recruitment
  2023-508212-38-00 4 2024-06-11 Multiple Myeloma
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma

Showing 265–288 of 457 trials